According to Coherent Market Insights, the Middle East and Turkey hemophilia treatment market to grow 4.2% CAGR

▴ hemophilia treatment
A CAGR of 4.2% during the forecast period (2019-2027), owing to increasing product launches by key players.

Middle East and Turkey hemophilia treatment market is expected to witness significant growth over the forecast period, owing to increasing demand for hemophilia treatment option such as recombinant coagulation factor and plasma-derived coagulation factor concentrates in emerging economies such as Saudi Arabia and Turkey, which is expected to drive the segment growth during the forecast period. For instance, according to the reports published by the World Federation of Hemophilia in 2016, demand for plasma-derived coagulation factors is high compared to recombinant coagulation concentrate. Moreover, plasma-derived coagulation concentrate are easily available in emerging economies such as Turkey and Saudi Arabia.

Moreover, increasing research and development for the development of novel therapies and rising incidence of hemophilia B is expected to drive the market growth. For instance, in August 2019, Mitsubishi Tanabe Pharma and Jichi Medical University entered into a collaboration to launch research study program for the development of gene therapy products, which can be used in the treatment of Hemophilia B. Moreover, according to the World Federation of Hemophilia 2018 statistics, around 1,084 cases of hemophilia B were reported in 2017, in Egypt.

Middle East, Asia Pacific, and Africa are expected to be the potential markets for hemophilia, owing to increasing healthcare awareness along with supportive government initiatives towards patient care and prevention of bleeding disorders. This is expected to create a favorable environment for market players. For instance, in July 2019, UAE Ministry of Health & Prevention (MoHAP) signed a Memorandum of Understanding (MoU) with Swedish Orphan Biovitrum AB Middle East and Bayti Home Healthcare. The initiative is for patients with Hemophilia A and Hemophilia B, who have difficulty in visiting medical centers and, in order to support and improve adherence to the treatment protocols prescribed by the doctors.

Among countries, Israel hemophilia treatment market is expected to witness significant growth over the forecast period, owing to presence of research facilities in Israel, which aids in conducting clinical studies for hemophilia therapy. For instance, in April 2019, Sheba Medical Center, Tel HaShomer, an Israel-based hospital, is the first hospital in Middle East region that conducted phase III trial on humans using the innovative gene therapy developed by the U.S.-based pharmaceutical company.

Tags : #cagr #middleeast #turkey #haemophilia #medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Smart Operating Rooms: The Future of Hospital OTNovember 21, 2026
Smartphone Diagnostics: Phones as Medical Screening ToolsNovember 21, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026